← Journal·NewsReferences paid reports

Lilly files orforglipron with the FDA.

The first oral GLP-1 with phase 3 evidence is now in front of the FDA. Decision likely H2 2026 or 2027.

Apr 22, 20262 min#glp-1#orforglipron#fda

Eli Lilly announced today that they've submitted orforglipron to the FDA for both type 2 diabetes and obesity. ACHIEVE-1 (T2D phase 3, Rosenstock et al., NEJM 2025, 40544435) showed 7.6% weight loss at the 36 mg dose over 40 weeks; ATTAIN-1 (obesity phase 3, Wharton et al., NEJM 2025, PMID 40960239) showed 11.2% at 72 weeks. ATTAIN-2 (obesity + T2D) read out at ~10.5%.

Why it matters:

orforglipron is the first receptor agonist that doesn't require an injection. It's a small-molecule mimetic, not a — but it activates the same receptor and produces similar (though slightly smaller) outcomes. It also has no food restrictions, unlike the older oral semaglutide formulation.

What we'll watch:

the FDA decision window (H2 2026 or 2027), pricing (Lilly hasn't signaled), and whether oral cannibalizes the injectable Mounjaro/Zepbound market or expands the total category.

Full deep dive: Orforglipron.